Publications by authors named "Norifumi Shuto"
Article Synopsis
- The study aimed to evaluate the effectiveness and safety of bitopertin, a drug that enhances glycine levels to potentially help with schizophrenia's negative symptoms, comparing Japanese and non-Japanese patients.
- Participants were given daily doses of bitopertin or a placebo for 8 weeks while being treated with other antipsychotics, and results were measured using a specific scale for negative symptoms (PANSS NSFS).
- The findings revealed that bitopertin was similarly effective for both Japanese and non-Japanese patients at lower doses, with no significant difference in safety or efficacy, although Japanese patients had a slightly lower response to placebo.
Background: Bitopertin, a glycine reuptake inhibitor, was investigated as a novel treatment for schizophrenia. We report all the results of a double-blind randomized study assessing safety and efficacy following 52-week adjunctive treatment with bitopertin in Japanese patients with schizophrenia.
Methods: This study enrolled Japanese outpatients with schizophrenia who met criteria for either "negative symptoms", i.